LEADER 02432nam 2200565Ia 450 001 9910574099703321 005 20170816113503.0 010 $a1-68367-122-8 010 $a1-283-03444-1 010 $a9786613034441 010 $a1-55581-685-1 035 $a(CKB)2670000000077763 035 $a(EBL)676288 035 $a(OCoLC)707608269 035 $a(SSID)ssj0000483660 035 $a(PQKBManifestationID)11303506 035 $a(PQKBTitleCode)TC0000483660 035 $a(PQKBWorkID)10573811 035 $a(PQKB)10076955 035 $a(MiAaPQ)EBC676288 035 $a(PPN)194692728 035 $a(EXLCZ)992670000000077763 100 $a20100506d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCryptococcus$b[electronic resource] $efrom human pathogen to model yeast /$fedited by Joseph Heitman ... [et al.] 210 $aWashington, DC $cASM Press$dc2011 215 $a1 online resource (647 p.) 300 $aDescription based upon print version of record. 311 $a1-55581-501-4 320 $aIncludes bibliographical references and index. 327 $aContents; Contributors; Foreword; Preface; SECTION I. GENERAL PRINCIPLES; SECTION II. GENETICS AND GENOMICS; SECTION III. SIGNALING AND VIRULENCE; SECTION IV. ENVIRONMENTAL INTERACTIONS AND POPULATION GENETICS; SECTION V. INTERACTIONS WITH THE IMMUNE SYSTEM; SECTION VI. PATHOGENESIS OF CRYPTOCOCCOSIS; SECTION VII. DIAGNOSIS, TREATMENT, PREVENTION, AND CLINICAL PERSPECTIVES; Index 330 $aFeaturing more than 100 expert authors from around the world, this book offers the full range of scientific and clinical perspectives needed to create this unique, comprehensive overview of Cryptococcus. It covers both the Cryptococcus neoformans and Cryptococcus gattii species, examining in detail the life cycle, pathophysiology, molecular biology, genetics, genomics, epidemiology, immunology, and clinical management of this encapsulated yeast. 606 $aCryptococcus 606 $aCryptococcaceae 615 0$aCryptococcus. 615 0$aCryptococcaceae. 676 $a579.5/9 701 $aHeitman$b Joseph$0890211 712 02$aAmerican Society for Microbiology. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910574099703321 996 $aCryptococcus$92869249 997 $aUNINA LEADER 01527cam a2200301 i 4500 001 991000063259707536 005 20020503113438.0 008 000626s1999 it abf 101 0 ita d 035 $ab10022284-39ule_inst 035 $aocm00009814$9ExL 040 $aDip.to Beni Culturali$bita 082 0 $a937.7 111 2 $aConvegno di Studi sulla Magna Grecia$n<38. ;$d1998 ;$cTaranto>$0391308 245 12$aL'Italia meridionale in età tardo antica :$batti del trentottesimo convegno di studi sulla Magna Grecia : Taranto 2-6 ottobre 1998 260 $aTaranto :$bIstituto per la Storia e l'Archeologia della Magna Grecia,$c1999 300 $a2 v. ;$c24 cm 505 1 $aV. 1.: 624 p. : ill. 505 1 $aV. 2.: P. 636-825, CV p. di tav. : ill. 651 4$aItalia meridionale$ySec. 4.-6. d. C.$vCongressi$y1998 907 $a.b10022284$b02-04-14$c31-05-02 912 $a991000063259707536 945 $aLE001 M I 39$cV. 1$g1$i2001000008407$lle001$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i10025388$z31-05-02 945 $aLE001 M I 39a$cV. 2$g1$i2001000008698$lle001$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i1002539x$z31-05-02 945 $aLE027 R-XXII 8 (38.1)$cV. 1$g1$i2027000103256$lle027$o-$pE52.50$q-$rn$so $t0$u0$v0$w0$x0$y.i1408479x$z08-06-05 945 $aLE027 R-XXII 8 (38.2)$cV. 2$g1$i2027000103263$lle027$o-$pE52.50$q-$rn$so $t0$u0$v0$w0$x0$y.i14084818$z08-06-05 996 $aItalia meridionale in età tardo antica$985150 997 $aUNISALENTO 998 $ale001$ale027$b01-01-00$cm$da $e-$fita$git $h2$i2 LEADER 03197oam 2200457 450 001 9910300068103321 005 20190911103512.0 010 $a1-4614-0766-4 024 7 $a10.1007/978-1-4614-0766-9 035 $a(OCoLC)878127422 035 $a(MiFhGG)GVRL6URB 035 $a(EXLCZ)992670000000421653 100 $a20140410d2014 uy 0 101 0 $aeng 135 $aurun|---uuuua 181 $ctxt 182 $cc 183 $acr 200 00$aRevision ACL reconstruction $eindications and technique /$fRobert G. Marx, editor 205 $a1st ed. 2014. 210 1$aNew York :$cSpringer,$d2014. 215 $a1 online resource (xxi, 273 pages) $cillustrations (some color) 225 0 $aGale eBooks 300 $aDescription based upon print version of record. 311 $a1-4614-0765-6 320 $aIncludes bibliographical references and index. 327 $aPatient-related risk factors for ACL graft failure -- Avoiding the failed ACL: how to prevent ACL tears before they occur -- Diagnosis of failed ACL reconstruction -- Biomechanics and Etiology of ACL graft failure -- Technical causes of ACL graft failure -- Indications for revision ACL reconstruction -- Preoperative planning for revision ACL reconstruction -- Graft selection for revision ACL reconstruction -- How to handle a poorly placed femoral tunnel -- How to handle a poorly placed tibial tunnel -- Fixation in revision ACL reconstruction -- Single stage ACL revision reconstruction: indications and technique -- Two stage ACL revision: indications and technique -- Revising failed double-bundle ACL reconstruction -- The role of lateral extra-arcticular augmentation in revision ACL reconstruction -- Managing the infected ACL reconstruction -- Meniscus allograft transplantation in revision ACL reconstruction -- Cartilage surgery in revision ACL reconstruction -- Medial collateral ligament laxity in revision ACL reconstruction -- Posterolateral corner deficiency in revision ACL reconstruction -- Osteotomy for slope correction following failed ACL reconstruction -- Osteotomy for malalignment following failed ACL reconstruction -- Navigation for revision ACL reconstruction -- Approach to the multiply revised ACL knee -- Outcomes of revision ACL. 330 $aAlthough anterior cruciate ligament (ACL) reconstruction has a high success rate, a substantial number of patients are left with unsatisfactory results. Revision ACL Reconstruction: Indications and Technique provides detailed strategies for planning and executing revision ACL reconstructions. Concise chapters by a leading group of international orthopedic surgeons cover the diagnosis of failed ACL reconstruction, patient evaluation, preoperative planning for revision ACL surgery, and complex technical considerations. 606 $aAnterior cruciate ligament$xSurgery 615 0$aAnterior cruciate ligament$xSurgery. 676 $a610 676 $a615.81 676 $a616.7 676 $a617 702 $aMarx$b Robert$g(Robert G.),$f1965- 801 0$bMiFhGG 801 1$bMiFhGG 906 $aBOOK 912 $a9910300068103321 996 $aRevision ACL Reconstruction$91522183 997 $aUNINA LEADER 02945nam 2200577 a 450 001 9910830264503321 005 20230213211623.0 010 $a1-280-58882-9 010 $a9786613618658 010 $a0-470-71936-2 010 $a0-470-71690-8 035 $a(CKB)1000000000687521 035 $a(EBL)703782 035 $a(SSID)ssj0000715138 035 $a(PQKBManifestationID)11377549 035 $a(PQKBTitleCode)TC0000715138 035 $a(PQKBWorkID)10700897 035 $a(PQKB)10229708 035 $a(MiAaPQ)EBC703782 035 $a(OCoLC)264621103 035 $a(EXLCZ)991000000000687521 100 $a20730216d1964 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCiba Foundation Symposium$b[electronic resource] $ecellular biology of myxovirus infections /$fedited by G.E.W. Wolstenholme and Julie Knight 210 $aBoston $cLittle, Brown and Co.$d1964 215 $a1 online resource (381 p.) 225 1 $aCiba Foundation symposium 300 $aDescription based upon print version of record. 311 $a0-470-72280-0 320 $aIncludes bibliographical references and indexes. 327 $aCELLULAR BIOLOGY OF MYXOVIRUS INFECTIONS; Contents; Chairman's opening remarks; Thestructureof myxoviruses and Its biological significance; Discussion; The various virus-specific units produced by myxovirus-infected cells; Discussion; Effects of inhibitors of nucleic acid synthesis on the production of myxoviruses; Discussion; Labelling of cells infected with myxoviruses; Discussion; Effect of actinomycin D on the replication of Newcastle disease and influenza viruses; Discussion; Ro?le of the surface state in the development of myxoviruses; Discussion 327 $aEffect of progressive iodination of influenza virus on i t s biological propertiesDiscussion; Structure of myxoviruses; Terminology and classification of myxoviruses; Classification of influenza A viruses; Genetic studies with influenza A virus; Discussion; Genetic variants of influenza virus which differ in reactivity with receptors and antibodies; Discussion; The antibody response; Analytical, serological and clinical experiences with the haemagglutinating subunits of influenza A virus; Discussion; Persistent infection of L cell cultures by myxoviruses; Discussion 327 $aCellular and humoral factors of defence against virus infectionDiscussion; General Discussion 410 0$aCiba Foundation symposium. 606 $aOrthomyxoviruses$vCongresses 615 0$aOrthomyxoviruses 676 $a576.6 701 $aWolstenholme$b G. E. W$g(Gordon Ethelbert Ward)$063039 701 $aKnight$b Julie$0512647 712 02$aCiba Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830264503321 996 $aCiba Foundation Symposium$93004923 997 $aUNINA